临床试验/NCT02217514

NCT02217514已完成1 期

Effects of 100 mg and 500 mg BI 44370 TA Orally Applied as 50 mg Tablets on the Pharmacokinetics of 2 mg Orally Administered Midazolam Solution. An Open-label, Randomised, Parallel Group, Fixed-sequence Study With Intraindividual Comparison of Midazolam Pharmacokinetics With and Without BI 44370 TA

Boehringer Ingelheim0 个研究点目标入组 48 人开始时间: 2008年2月最近更新: 2014年8月15日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Boehringer Ingelheim
入组人数: 48
主要终点: AUC0-infinity (area under the concentration-time curve of midazolam in plasma over the time interval from 0 extrapolated to infinity)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Evaluation of the long-term (48 h) and short-term (1 h) effects of BI 44370 BS on the pharmacokinetics of midazolam as marker of a possible inhibition of CYP 3A4; safety and tolerability.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 21 Years 至 50 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
•Age ≥21 and Age ≤50 years
•BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
•Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation.

排除标准

•Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of clinical relevance
•Any evidence of a clinically relevant concomitant disease
•Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
•Surgery of the gastrointestinal tract (except appendectomy)
•Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
•History of relevant orthostatic hypotension, fainting spells or blackouts
•Chronic or relevant acute infections
•History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
•Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
•Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
•Participation in another trial with an investigational drug within 30 days prior to administration or during the trial
•Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
•Inability to refrain from smoking on trial days
•Alcohol abuse (more than 60 g/day)
•Drug abuse
•Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
•Excessive physical activities (within one week prior to administration or during the trial)
•Any laboratory value outside the reference range that is of clinical relevance
•Inability to comply with dietary regimen of trial site
•A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >470 ms);
•A history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
•For Male Subjects:
•Not willing to use adequate contraception (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device (IUD)) during the whole study period from the time of the first intake of study drug until three months after the last intake
•For Female Subjects:
•Pregnancy
•Positive pregnancy test
•No adequate contraception (adequate contraception e.g. sterilisation, intrauterine pessary (IUP), oral contraceptives)
•Inability to maintain this adequate contraception during the whole study period during the whole study period from the time of the first intake of study drug until one month after the last intake

研究组 & 干预措施

Treatment sequence 1 in male subjects

Experimental

Midazolam alone and 1 h after low dose BI44370BS in male subjects

干预措施: Midazolam (Drug)

Treatment sequence 1 in male subjects

Experimental

Midazolam alone and 1 h after low dose BI44370BS in male subjects

干预措施: BI 44370 low dose (Drug)

Treatment sequence 1 in female subjects

Experimental

Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects

干预措施: Midazolam (Drug)

Treatment sequence 1 in female subjects

Experimental

Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects

干预措施: BI 44370 low dose (Drug)

Treatment sequence 1 in female subjects

Experimental

Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects

干预措施: BI 44370 medium dose (Drug)

Treatment sequence 2

Experimental

Midazolam before and 48 h after high dose BI44370BS

干预措施: Midazolam (Drug)

Treatment sequence 2

Experimental

Midazolam before and 48 h after high dose BI44370BS

干预措施: BI 44370 high dose (Drug)

Treatment sequence 3

Experimental

Midazolam before and 24 h after high dose BI44370BS

干预措施: Midazolam (Drug)

Treatment sequence 3

Experimental

Midazolam before and 24 h after high dose BI44370BS

干预措施: BI 44370 high dose (Drug)

Treatment sequence 4

Experimental

Midazolam before and 1 h after high dose BI44370BS

干预措施: Midazolam (Drug)

Treatment sequence 4

Experimental

Midazolam before and 1 h after high dose BI44370BS

干预措施: BI 44370 high dose (Drug)

结局指标

主要结局

AUC0-infinity (area under the concentration-time curve of midazolam in plasma over the time interval from 0 extrapolated to infinity)

时间窗: up to 24 hours after drug administration

Cmax (maximum concentration of midazolam in plasma)

时间窗: up to 24 hours after drug administration

AUC0-tz (area under the concentration-time curve of midazolam in plasma over the time interval from 0 to the time of the last quantifiable data point)

时间窗: up to 24 hours after drug administration

次要结局

Cmax (maximum measured concentration of the analyte in plasma)(Up to 48 hours after drug administration)
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 48 hours after drug administration)
%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(up to 48 hours after drug administration)
λz (terminal rate constant in plasma)(up to 48 hours after drug administration)
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 48 hours after drug administration)
Assessment of tolerability by investigator on a 4-point scale(up to 8 days after last drug administration)
AUC0-tz (area under the concentration-time curve of the analyte in plasma in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 48 hours after drug administration)
AUCt1-t2 (Area under the concentration-time curve of the analyte in plasma over the time interval t1 to t2)(up to 48 hours after drug administration)
tmax (time from dosing to maximum measured concentration)(up to 48 hours after drug administration)
Aet1-t2 (amount of BI 44370 BS eliminated in urine from the time point t1 to time point t2)(up to 24 hours after drug administration)
t1/2 (terminal half-life of the analyte in plasma)(up to 48 hours after drug administration)
MRTp.o. (mean residence time of the analyte in the body after oral administration)(up to 48 hours after drug administration)
CL/F (total/apparent clearance of the analyte in plasma after extravascular administration)(up to 48 hours after drug administration)
fet1-t2 (fraction of BI 44370 BS eliminated in urine from time point t1 to time point t2)(up to 24 hours after drug administration)
CLR,t1-t2 (renal clearance of BI 44370 BS from the time point t1 until the time point t2)(up to 24 hours after drug administration)
ratio of AUC0-∞ 1-OH-midazolam / AUC0-∞ midazolam(up to 48 hours after drug administration)
Number of patients with adverse events(up to 8 days after last drug administration)

研究者

发起方

Boehringer Ingelheim

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male VolunteersHealthy

NCT02215018Boehringer Ingelheim56

已完成

1 期

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female VolunteersHealthy

NCT02215759Boehringer Ingelheim34

已完成

1 期

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideParkinson's Disease (PD)

NCT02169466Bial - Portela C S.A.22

已完成

1 期

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideParkinson's Disease (PD)

NCT02169895Bial - Portela C S.A.16

已完成

1 期

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaParkinson's Disease (PD)

NCT02169453Bial - Portela C S.A.12